NASDAQ
07.08.26 | 21:59
4,210 US-Dollar
-0,24 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Zentalis Pharmaceuticals GAAP EPS of -$0.59 misses by $0.10 | 2 | Seeking Alpha | ||
| Mo | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 17.07. | Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | 3 | GlobeNewswire (USA) | ||
| 17.07. | Mizuho initiates Zentalis Pharmaceuticals stock at Outperform | 3 | Investing.com | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 22.05. | H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data | 1 | Investing.com | ||
| 22.05. | H.C. Wainwright bestätigt Kaufempfehlung für Zentalis nach Daten zu Eierstockkrebs | 27 | Investing.com Deutsch | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 22.05. | Zentalis to present ovarian cancer trial data at ASCO meeting | 2 | Investing.com | ||
| 21.05. | Zentalis präsentiert auf Jährlicher ASCO-Tagung Studiendaten zu Eierstockkrebs | 2 | Investing.com Deutsch | ||
| 21.05. | Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | 3 | GlobeNewswire (USA) | ||
| 21.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 21.04. | Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer | 2 | GlobeNewswire (USA) | ||
| 17.04. | Zentalis präsentiert Daten zu Krebsmedikament Azenosertib - Aktie unter Druck | 3 | Investing.com Deutsch | ||
| 17.04. | Zentalis presents preclinical data on cancer drug azenosertib | 10 | Investing.com | ||
| 17.04. | Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 51,36 | +0,37 % | Moderna startet Phase-1-Studie mit Ebola-Impfstoffkandidat | Moderna hat eine Phase-1-Studie mit seinem Impfstoffkandidaten mRNA-1469 gegen das Bundibugyo-Ebolavirus (BDBV) begonnen. Nach der Genehmigung durch die kanadische Gesundheitsbehörde wurden in Kanada... ► Artikel lesen | |
| VALNEVA | 2,291 | +0,04 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| VIVOSIM LABS | 0,468 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| SAREPTA THERAPEUTICS | 14,720 | +1,38 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| IMMUNITYBIO | 6,550 | -0,76 % | IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake | ||
| CARDIFF ONCOLOGY | 0,833 | -3,48 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| ALDEYRA | 1,350 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| IOVANCE BIOTHERAPEUTICS | 5,500 | +0,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| GUARDANT HEALTH | 137,38 | -5,78 % | Stifel raises Guardant Health stock price target on strong Q2 results | ||
| TRAWS PHARMA | 0,543 | +2,05 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -3,14 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,098 | +0,27 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,210 Euro und damit -0,24 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.